Subtopic Deep Dive
Oxaliplatin-Induced Neuropathy
Research Guide
What is Oxaliplatin-Induced Neuropathy?
Oxaliplatin-induced neuropathy is a dose-limiting peripheral neurotoxicity characterized by acute cold hypersensitivity and chronic sensory deficits in colorectal cancer patients receiving oxaliplatin chemotherapy.
This condition manifests as acute symptoms like paresthesias triggered by cold exposure and chronic axonal degeneration, affecting 30-50% of patients and leading to dose reductions (Hershman et al., 2014, 1196 citations). Research identifies sodium channel alterations and mitochondrial dysfunction as key mechanisms (Starobova and Vetter, 2017, 597 citations). Over 10 major reviews document its prevalence, risk factors, and lack of effective prophylaxis (Zajączkowska et al., 2019, 755 citations).
Why It Matters
Oxaliplatin-induced neuropathy causes treatment discontinuation in up to 50% of colorectal cancer cases, compromising survival outcomes and quality of life (Hershman et al., 2014). ASCO guidelines highlight unmet needs in prevention, with no FDA-approved therapies despite extensive trials (Hershman et al., 2014; Jordan et al., 2020). Targeted interventions could reduce dose reductions, enabling full regimens; genetic predictors identified in reviews offer personalization potential (Argyriou et al., 2008; Kerckhove et al., 2017). Real-world impact includes survivor disability, with chronic pain persisting years post-treatment (Kerckhove et al., 2017, 344 citations).
Key Research Challenges
Incomplete Mechanistic Understanding
Oxaliplatin disrupts sodium channels and DRG neurons, but exact pathways linking acute cold allodynia to chronic axonopathy remain unclear (Starobova and Vetter, 2017). Animal models fail to fully replicate human symptoms, hindering translation (Zajączkowska et al., 2019). Over 755-cited reviews note persistent gaps in mitochondrial and inflammatory contributions (Zajączkowska et al., 2019).
Lack of Effective Prophylaxis
ASCO guidelines find insufficient evidence for duloxetine or cryotherapy in oxaliplatin neuropathy prevention (Hershman et al., 2014). Dose reductions occur in 30-50% of cases without reliable interventions (Alcindor and Beauger, 2011). ESMO guidelines confirm no standard prophylaxis exists (Jordan et al., 2020).
Individual Risk Prediction Failure
Genetic and clinical predictors like AGXT polymorphisms show inconsistent replication across cohorts (Kerckhove et al., 2017). Patient factors including diabetes exacerbate risk, but no validated screening tools exist (Grisold et al., 2012). Reviews of 271+ cited works highlight need for biomarkers (Argyriou et al., 2014).
Essential Papers
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman, Christina Lacchetti, Robert H. Dworkin et al. · 2014 · Journal of Clinical Oncology · 1.2K citations
Purpose To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Met...
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Renata Zajączkowska, Magdalena Kocot-Kępska, Wojciech Leppert et al. · 2019 · International Journal of Molecular Sciences · 755 citations
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sens...
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova, Irina Vetter · 2017 · Frontiers in Molecular Neuroscience · 597 citations
Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment, and severely affe...
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
Wolfgang Grisold, Guido Cavaletti, Anthony J. Windebank · 2012 · Neuro-Oncology · 477 citations
Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem. Contrary to hematologic adverse effects, which can be treated with hematopoetic growth factors, neither ...
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Thierry Alcindor, N. Beauger · 2011 · Current Oncology · 412 citations
Objective: To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy. Methods of Study Selection: We searched the PubMed and PubChem databases b...
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review
Nicolas Kerckhove, Aurore Collin, Sakahlé Condé et al. · 2017 · Frontiers in Pharmacology · 344 citations
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy-induced peripheral neuropathy...
A review on oxaliplatin-induced peripheral nerve damage
Andreas A. Argyriou, Panagiotis Polychronopoulos, Gregoris Iconomou et al. · 2008 · Cancer Treatment Reviews · 324 citations
Reading Guide
Foundational Papers
Start with Hershman et al. (2014, 1196 citations) for ASCO clinical guidelines on CIPN management, then Grisold et al. (2012, 477 citations) for diagnosis/prevention basics, and Argyriou et al. (2008, 324 citations) for oxaliplatin-specific pathology.
Recent Advances
Study Zajączkowska et al. (2019, 755 citations) for updated mechanisms, Kerckhove et al. (2017, 344 citations) for long-term effects, and Jordan et al. (2020, 295 citations) for ESMO guidelines.
Core Methods
Core techniques involve clinical grading (e.g., NCI-CTCAE), rodent cold-plate assays for hypersensitivity, patch-clamp electrophysiology on sodium channels, and systematic meta-analyses of intervention trials.
How PapersFlow Helps You Research Oxaliplatin-Induced Neuropathy
Discover & Search
Research Agent uses searchPapers('oxaliplatin neuropathy mechanisms') to retrieve Hershman et al. (2014, 1196 citations), then citationGraph to map 755+ citing works like Zajączkowska et al. (2019), and findSimilarPapers to uncover oxaliplatin-specific reviews. exaSearch drills into cold hypersensitivity subtypes from 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent on Starobova and Vetter (2017) to extract sodium channel data, verifyResponse with CoVe against Hershman guidelines for evidence alignment, and runPythonAnalysis to meta-analyze prevalence stats (e.g., pandas on 30-50% dose reduction rates). GRADE grading scores ASCO recommendations as moderate-quality evidence.
Synthesize & Write
Synthesis Agent detects gaps like prophylaxis failures via contradiction flagging across Jordan et al. (2020) and Kerckhove et al. (2017); Writing Agent uses latexEditText for neuropathy mechanism sections, latexSyncCitations to integrate 10 key papers, and latexCompile for publication-ready reviews. exportMermaid visualizes acute vs. chronic pathway diagrams.
Use Cases
"Analyze prevalence and risk factors of oxaliplatin neuropathy from top 20 papers using statistics."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of 30-50% rates from Hershman 2014, Kerckhove 2017) → CSV export of risk odds ratios.
"Write LaTeX review section on oxaliplatin cold hypersensitivity mechanisms with citations."
Research Agent → citationGraph (Starobova 2017) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF with cited pathway figure.
"Find GitHub code for oxaliplatin neuropathy simulation models from papers."
Research Agent → paperExtractUrls (from Zajączkowska 2019) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python neuron simulation sandbox via runPythonAnalysis.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ oxaliplatin CIPN papers) → DeepScan(7-step verification with GRADE on Hershman 2014) → structured report on mechanisms. Theorizer generates hypotheses linking sodium channels to cold allodynia from Starobova (2017) + Kerckhove (2017). DeepScan applies CoVe chain to validate genetic risk claims across cohorts.
Frequently Asked Questions
What defines oxaliplatin-induced neuropathy?
It features acute cold-triggered paresthesias and chronic sensory loss from dorsal root ganglion damage, limiting oxaliplatin dosing in 30-50% of colorectal cancer patients (Hershman et al., 2014; Argyriou et al., 2008).
What are main research methods?
Methods include patient cohort studies, animal DRG neuron models, and systematic reviews assessing interventions like duloxetine; ASCO analyzed 54 trials for guidelines (Hershman et al., 2014; Starobova and Vetter, 2017).
What are key papers?
Hershman et al. (2014, 1196 citations) provides ASCO guidelines; Zajączkowska et al. (2019, 755 citations) reviews mechanisms; Argyriou et al. (2008, 324 citations) focuses on oxaliplatin nerve damage.
What open problems exist?
No validated prophylaxis or genetic predictors exist; chronic persistence mechanisms and effective symptom management remain unsolved (Jordan et al., 2020; Kerckhove et al., 2017).
Research Cancer Treatment and Pharmacology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Oxaliplatin-Induced Neuropathy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Treatment and Pharmacology Research Guide